| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Molecular Targets, and Chemical Biology |
1 Division of Surgical Oncology, Graduate School of Medicine and 2 Biomedical Engineering Research, Organization, Tohoku University, Sendai, Japan
Requests for reprints: Hideo Higuchi, Biomedical Engineering Research Organization, Tohoku University, Engineering research Lab complex, 6-6-11 Aramaki, Aoba-ku, Sendai, Miyagi 980-8578, Japan. Phone: 81-22-795-4735; Fax: 81-22-795-5753; E-mail: higuchi{at}tubero.tohoku.ac.jp.
Studies with tracking of single nanoparticles are providing new insights into the interactions and processes involved in the transport of drug carriers in living mice. Here, we report the tracking of a single particle quantum dot (Qdot) conjugated with tumor-targeting antibody in tumors of living mice using a dorsal skinfold chamber and a high-speed confocal microscope with a high-sensitivity camera. Qdot labeled with the monoclonal anti-HER2 antibody was injected into mice with HER2-overexpressing breast cancer to analyze the molecular processes of its mechanistic delivery to the tumor. Movement of single complexes of the Qdot-antibody could be clearly observed at 30 frames/s inside the tumor through a dorsal skinfold chamber. We successfully identified six processes of delivery: initially in the circulation within a blood vessel, during extravasation, in the extracelullar region, binding to HER2 on the cell membrane, moving from the cell membrane to the perinuclear region, and in the perinuclear region. The six processes were quantitatively analyzed to understand the rate-limiting constraints on Qdot-antibody delivery. The movement of the complexes at each stage was "stop-and-go." The image analysis of the delivery processes of single particles in vivo provides valuable information on antibody-conjugated therapeutic nanoparticles, which will be useful in increasing therapeutic efficacy. [Cancer Res 2007;67(3):113844]
This article has been cited by other articles:
![]() |
S. B. Lee, M. Hassan, R. Fisher, O. Chertov, V. Chernomordik, G. Kramer-Marek, A. Gandjbakhche, and J. Capala Affibody Molecules for In vivo Characterization of HER2-Positive Tumors by Near-Infrared Imaging Clin. Cancer Res., June 15, 2008; 14(12): 3840 - 3849. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Cheng, O. P. De Jesus, M. Namavari, A. De, J. Levi, J. M. Webster, R. Zhang, B. Lee, F. A. Syud, and S. S. Gambhir Small-Animal PET Imaging of Human Epidermal Growth Factor Receptor Type 2 Expression with Site-Specific 18F-Labeled Protein Scaffold Molecules J. Nucl. Med., May 1, 2008; 49(5): 804 - 813. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Keren, C. Zavaleta, Z. Cheng, A. de la Zerda, O. Gheysens, and S. S. Gambhir Noninvasive molecular imaging of small living subjects using Raman spectroscopy PNAS, April 15, 2008; 105(15): 5844 - 5849. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H.E. Baker, K. E. Lindquist, L. A. Huxham, A. H. Kyle, J. T. Sy, and A. I. Minchinton Direct Visualization of Heterogeneous Extravascular Distribution of Trastuzumab in Human Epidermal Growth Factor Receptor Type 2 Overexpressing Xenografts Clin. Cancer Res., April 1, 2008; 14(7): 2171 - 2179. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Diagaradjane, J. M. Orenstein-Cardona, N. E. Colon-Casasnovas, A. Deorukhkar, S. Shentu, N. Kuno, D. L. Schwartz, J. G. Gelovani, and S. Krishnan Imaging Epidermal Growth Factor Receptor Expression In vivo: Pharmacokinetic and Biodistribution Characterization of a Bioconjugated Quantum Dot Nanoprobe Clin. Cancer Res., February 1, 2008; 14(3): 731 - 741. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Cai, K. Chen, Z.-B. Li, S. S. Gambhir, and X. Chen Dual-Function Probe for PET and Near-Infrared Fluorescence Imaging of Tumor Vasculature J. Nucl. Med., November 1, 2007; 48(11): 1862 - 1870. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Sampath, S. Kwon, S. Ke, W. Wang, R. Schiff, M. E. Mawad, and E. M. Sevick-Muraca Dual-Labeled Trastuzumab-Based Imaging Agent for the Detection of Human Epidermal Growth Factor Receptor 2 Overexpression in Breast Cancer J. Nucl. Med., September 1, 2007; 48(9): 1501 - 1510. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |